Unity Biotechnology Inc. (NASDAQ: UBX): The stock forecast for 2022 is still weak, with a 35.3 percent downward revision.
Based on a mean score of 2.40, the shares of Unity Biotechnology Inc. obtained an Overweight consensus recommendation. If we look at the data even more closely, we can see that 0 out of 7 analysts rank the stock as a Sell, while 0 others assess it as Overweight. UBX was classified as a Hold by 2 analysts, a Buy by 5 analysts, and Underweight by 0 analysts. For the current quarter, Unity Biotechnology Inc. is predicted to post earnings per share of -$0.38.
With a performance of 5.80 percent at the end of recent trade, UBX has immediately shown a positive trend. Over the previous five days, the performance has stayed in the red. The stock’s daily price grew by 7.59 percent after reaching weekly highs of 1.5800 on Friday, December 31, 2011. The stock is presently down -72.14 percent year to date, but it is still down -6.41 percent in the previous five days. Unity Biotechnology Inc. (NASDAQ:UBX), on the other side, has lost -24.35 percent in the last 30 days.
Wall Street analysts have set an average price target of $7.00, implying that bulls must grow their stock price by 79.14 percent from its present level. According to analyst forecasts, UBX will trade at a low of $4.00 and a high of $12.00. To reach the expected high, the stock would have to fall -721.92 percent from its present level, while to reach the projected low, the stock would have to fall -173.97 percent from its current position.
Estimates and predictions for Unity Biotechnology Inc. (UBX)
Furthermore, experts have opted to raise their revenue forecasts for fiscal year 2022. The rating companies expect that sales will increase by 26.90 percent this quarter and decline by -21.60 percent the following quarter.
marketingsentinel.com is the source for this information.
The Future of Unity Biotechnology Inc. (NASDAQ: UBX) in 2022
The stock completed the day at $1.83, falling within a range of $1.65 and $1.89, as active traders watched the market movement. The beta (5-year monthly) value was 0.13. The peak point of the stock’s 52-week performance was $9.78, while the low point was $1.23. Over the last month, UBX has varied by -11.17 percent on average.
Investors are looking forward to this quarter’s results, which are slated for March 21, 2022 – March 25, 2022, because Unity Biotechnology Inc.’s market capitalization is now around $91.17 million. As a consequence, before the firm releases its earnings report, investors may wish to see a price increase in the stock. Analysts estimate the company’s earnings per share (EPS) to be -$0.34, rising to -$0.27 for fiscal year -$1.26 and then to about -$1.55 by fiscal year 2022, according to analysts. According to data, EPS growth in 2022 is predicted to be 31.50 percent, while EPS growth in the following year is expected to be -23.00 percent.
There have been no upward or downward revisions for the firm in the previous seven days, which might be a good sign for gaining insight into short-term price volatility. We can see that UBX’s technical picture reveals that short-term indications indicate that the stock is on average a 50% Sell. Medium-term indications, on the other hand, have categorised the stock as a 100 percent sell, while long-term indicators, on average, have indicated that it is a 100 percent sell.
On a scale of 1.00 to 5.00, 7 analyst(s) have provided their ratings on the stock’s projected evaluation, indicating a strong buy to a strong sell recommendation. 1 analyst rated the stock as a Hold, 6 rated it as a Buy, and 0 ranked the UBX stock as Overweight. Meanwhile, 0 analyst(s) rate the stock as Underweight, while 0 rate it as a Sell. Since a result, investors who want to grow their holdings of the company’s stock will be able to do so, as the stock’s average rating is Buy.
The PEG ratio for the company is roughly 0, according to technical analysis, and the price of UBX is now trading nearly 3.57 percent and -19.58 percent away from the simple moving averages for the 20 and 50 days, respectively. The Relative Strength Index (RSI, 14) is now at 47.19, while the 7-day volatility ratio is at 14.80 percent, and the 30-day volatility ratio is at 11.96 percent. Unity Biotechnology Inc. (UBX) also has a beta of 0.02 and an average true range (ATR) of 0.20. Over the next 52 weeks, the company’s stock is expected to trade at an average price of $7.00, with a low of $4.00 and a high of $12.00. According to these price projections, the low is -139.52 percent below current price, while the yearly target high requires a rise of -618.56 percent. Furthermore, investors are likely to embrace analysts’ consensus price of $6.00, which represents a -259.28 percent reduction from current levels.
stocksregister.com is the source for this information.
At $1.30, Unity Biotechnology Inc. (UBX) is worth a bite.
Unity Biotechnology Inc. (NASDAQ:UBX) fell -4.41 percent from its previous day’s finish on Wednesday, December 29, as purchasers pulled the stock’s value down to $1.30.
Looking at the stock’s price trend, the stock closed at $1.36 in the most recent trading session, ranging in a range of $1.23 to $1.37. The 5-year monthly beta value was 0.23. In terms of its 52-week performance, the 52-week high and low were $9.78 and $1.31, respectively. Over the last month, UBX has lost 37.50 percent of its value.
We’ve set up an alert service to assist clever investors in taking full advantage of small-cap stocks that are poised for large gains.
The market capitalization of Unity Biotechnology Inc. is now around $74.09 million, with investors anticipating the company’s earnings release on March 21, 2022 – March 25, 2022. Analysts expect the company’s earnings per share (EPS) to be -$0.38, with EPS expected to rise to -$1.49 in fiscal year 2021 and about -$1.31 in fiscal year 2022. According to the statistics, EPS growth is predicted to be 19.00% in 2021 and 12.10% the following year.
Revisions may be used to provide insight into short-term price movement, and there have been no upward or downward revisions in the last seven days for the firm (s). In terms of the stock’s technical picture, short term indications show that UBX is a 100 percent sell on average. On the other side, medium-term indications show that the stock is a 100 percent sell, while long-term indicators imply that the stock is a 100 percent sell.
On a scale of 1.00 to 5.00, 7 analyst(s) have offered their prognosis ratings for the stock, ranging from a strong buy to a strong sell recommendation. UBX has a Hold rating from 2 analysts, a Buy recommendation from 5 analysts, and an Overweight rating from 0 analysts. Meanwhile, 0 analyst(s) recommend Underweight and 0 recommend Sell. As a result, the stock’s average rating is Overweight, which may present an opportunity for investors looking to increase their holdings of the company’s shares.
UBX is now trading at a discount to its 20-day and 50-day simple moving averages of -23.53 percent and -39.80 percent, respectively. The Relative Strength Index (RSI, 14) is now at 30.07, with a 7-day volatility ratio of 9.79 percent and a 30-day volatility ratio of 11.21 percent. Unity Biotechnology Inc. (UBX) also has a 0.09 beta and a 0.17 average true range (ATR). Analysts expect the company’s stock to trade at $7.00 in the next 52 weeks, with a low of $4.00 and a high of $12.00. In terms of price objectives, the low is -207.69 percent below current levels, while the yearly target high requires a rise of -823.08 percent. Nonetheless, a -361.54 percent increase to $6.00, the experts’ consensus price, is sure to please investors.
When comparing Unity Biotechnology Inc. (UBX) to its counterparts in the market, it appears that the former has done much worse. The intraday price of UBX has moved -4.41 percent in the last session and -74.71 percent over the last year, according to data. In other news, the S&P 500 and Dow Jones Industrial Averages are up 0.14 percent and 0.25 percent, respectively, in the most recent trading session.
stocksregister.com is the source of this information
The price target for Unity Biotechnology Inc. (NASDAQ:UBX) for the next 12 months is $12.00.
Unity Biotechnology Inc. (NASDAQ:UBX) had 0.86 million shares traded in the previous trading session, with a beta of 0.11. The company’s current per share price of $1.56, which was trading at $0.02 or 1.30 percent lower at the ring of the bell on the day, gives it a market value of $86.67 million dollars. The stock’s ending price indicates a premium of 8.33 percent over its 52-week low price of $1.43, suggesting a discount of -526.92 percent from its 52-week high price of $9.78. If we look at the company’s average trading volume for the last three months, it is 890.45K.
Analysts have assigned a mean rating of 2.40 to Unity Biotechnology Inc. (UBX), with an average recommendation of an Overweight. When the data is broken down, it shows that out of the 7 analysts that cover the stock, 0 advised a Sell recommendation and 0 recommended an Overweight rating. 2 people recommended the stock as a Hold, while 5 people recommended it as a Buy. It was rated as an Underweight by 0 analyst(s). In the current quarter, the firm is predicted to earn -$0.38 per share.
Trade data for Unity Biotechnology Inc. (NASDAQ:UBX).
In the previous five days, UBX has remained in the green, reaching a week-high on Friday, December 17th, when the stock hit $1.56, adding 5.45 percent to its value on the day. Unity Biotechnology Inc.’s shares have moved 1.30 percent in the last five days, with a year-to-date change of -70.23 percent. Unity Biotechnology Inc. (NASDAQ:UBX) has had a 30-day performance of -33.62 percent.
The company has an average price target of $7.00 among Wall Street analysts, implying an increase of 77.71 percent from its present price. The stock has a low price goal of $4.00 and a high price target of $12.00, according to analysts. As a result, hitting the projected high would result in a -669.23 percent reduction in the stock’s current price, whilst reaching the targeted low would result in a -156.41 percent drop in the stock’s present value.
Estimates and predictions for Unity Biotechnology Inc. (UBX)
According to statistics, Unity Biotechnology Inc.’s score is greater than that of other firms in the relevant industry. In the last six months, the company’s shares have lost 64.06 percent of their value, with an annual growth rate of 28.49 percent vs 7.50 for the industry. Aside from that, the firm increased its revenue projections for fiscal year 2021. The firm anticipates a 26.90 percent increase in sales in the current quarter and a -21.60 percent reduction in the next quarter.
Dividends from UBX
Unity Biotechnology Inc. is more likely to release its next quarterly report between March 21 and March 25, and investors are optimistic that the business would announce higher current-quarter payouts despite its escalating financial problems.
Major shareholders of Unity Biotechnology Inc. (NASDAQ:UBX)
Insiders own 6.41 percent of the company’s total shares, while institutions own 62.81 percent, with a share float of 67.11 percent. Investors also pay special attention to the amount of corporate investors in a company, which in the case of Unity Biotechnology Inc. is 62.81 percent institutions. With 4.12 million shares valued at $24.69 million, FMR, LLC is the largest institutional holding at UBX. It held 7.50 percent of the company’s outstanding shares as of March 30, 2021.
Baillie Gifford and Company, the second largest institutional investor, had around 3.8 million shares on March 30, 2021. The number of shares indicates the firm’s ownership of 6.93 percent of all outstanding shares, valued at $22.82 million.
marketingsentinel.com is the source of this information
Should You Buy Unity Biotechnology Inc (UBX) After Its Stock Drops -15.45% This Week?
The stock of Unity Biotechnology Inc (UBX) has dropped -65.51 percent in the last year, and Wall Street analysts have given it a Buy recommendation.
UBX stock receives a 34 out of 100 rating from InvestorsObserver’s own grading methodology. A short-term technical score of 4 has an impact on that ranking. A long-term technical score of 4 is also included in UBX’s ranking. UBX has a basic score of 95. UBX stock has a mean target price of $7.67, in addition to the average Wall Street analyst rating. This suggests that experts predict the stock will rise 268.56% in the next year.
What is the current state of the UBX stock?
As of 10:09 a.m. on Tuesday, Nov 30, Unity Biotechnology Inc (UBX) stock is flat 0%, while the S&P 500 is down -0.39%. On volume of 130,957 shares, UBX is unchanged at $0.00 from its previous closing price of $2.08. The S&P 500 has gained 28.03 percent in the last year, whereas UBX has lost 65.51 percent. Over the last year, UBX has lost -$1.28 per share.
investorsobserver.com is the source of this information
The stock of Unity Biotechnology, Inc. (UBX) has dropped after the company released data from a Phase I Vascular Eye Disease trial.
What is the situation with UBX?
UNITY Biotechnology, Inc. (UBX) released 12-week results from its UBX1325 Phase 1 safety trial in patients with advanced diabetic macular edoema (DME) and wet age-related macular degeneration (AMD).
Only individuals for whom anti-VEGF medication was no longer regarded effective were recruited in the study.
Unity is a biotechnology business that is working on treatments to reduce, stop, or reverse ageing disorders.
UBX shares fell 13.48 percent to $2.41 on Tuesday morning.
What does this imply for Unity Biotechnology as a company?
UBX1325 is noteworthy since it is a small molecule Bcl-xL inhibitor and the first senolytic therapeutic candidate for ophthalmologic illnesses that targets a different biologic route than anti-VEGF treatments.
The results indicated substantial and persistent responses after a single injection of UBX1325 for up to 12 weeks, according to Unity, and contributed significantly to the previously disclosed 8-week dataset, which offered preliminary indications of effectiveness.
“It’s encouraging to see improvements in vision sustained over three months after a single dose in these patients with advanced vascular eye disease,” said Robert Bhisitkul, M.D., Ph.D., professor of ophthalmology and director of the Retina Fellowship at the University of California, San Francisco.
“Because patients who do not respond to conventional treatment have few choices, a new therapeutic strategy like UBX1325 might be a considerable benefit as an alternative or complement to anti-VEGF medications.”
The study’s 24-week results are expected by the end of the year.
Unity Biotechnology Inc develops treatments to prevent, slow, or reverse aging-related disorders. The firm focuses on senescent cell clearance and the development of senolytic drugs. Its treatments target senescent cells’ weaknesses in order to eliminate them from the human body while keeping healthy cells intact. The company specialises in age-related ailments such osteoarthritis, eye diseases, and respiratory diseases.
.investorsobserver.com is the source of this information
Disclaimer: The views and investment tips expressed by investment expert on Stock consultant bihar are Sourced From Brokerage Firms Research Reports & Market Experts Opinion. We advises users to consult your investment advisor before taking any decisions. Our Website Contain Demat Account & Algo Trading affliate Link. If You’ll Register Through Our Link We May Get Profit.
More US Stocks Forecast Updates:
- Organon & Co Stock Price Target Forecast, (OGN) Prediction 2022, 2023, 2025, 2030
- Sino United Worldwide Stock Price Target Forecast, (SUIC) Prediction 2022, 2023, 2025, 2030
- Futu Holdings Ltd Stock Price Target Forecast, (FUTU) Prediction 2022, 2023, 2025, 2030
- Virpax Pharmaceuticals Inc Stock Price Target Forecast, (VRPX) Prediction 2022, 2023, 2025, 2030